Skip to content

Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia

A Comparative Controlled Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00129610
Enrollment
90
Registered
2005-08-12
Start date
2004-01-31
Completion date
Unknown
Last updated
2007-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Agoraphobia, Panic Disorder

Keywords

Agoraphobia, panic disorder, Virtual Reality Therapy, Cognitive Behavior Therapy, cognition, spatial cognition, PANIC DISORDER WITH AGORAPHOBIA

Brief summary

The study aims at comparing virtual reality therapy (VRT) with a usual cognitive behavior therapy (CBT) program for agoraphobia. A waiting list represents the control condition. The investigators' purpose is to test a pure VRT compared with a pure CBT, as previous works suggest that the combination of the two methods are clinically effective. Patients receive a two-page information leaflet about the trial and sign an informed consent. After the first evaluation, they are randomized, in three centers (Lyon, Paris, Luxemburg), either to VRT (12 sessions) or CBT (12 sessions), or a waiting-list control condition for three months. After three months the waiting list is randomized to VRT or CBT. The follow-up is one year from entry into the active part of the trial.

Interventions

BEHAVIORALVirtual Reality Therapy
BEHAVIORALCognitive Behavior Therapy

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
ECT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* The study includes 90 patients, aged from 18 to 60, with DSM-4 panic disorder with agoraphobia. * Patients should not be clinically depressed and present a Hamilton Scale of Depression score of less than 18.

Exclusion criteria

* Patients with active medication (antidepressants, neuroleptics, mood stabilizers, benzodiazepines, Kava Kava, or hypericum) or street drugs. Minor herbal medicine is tolerated.

Design outcomes

Primary

MeasureTime frame
The response criterion is a decrease of 50% of the agoraphobia subscore on the Fear Questionnaire

Secondary

MeasureTime frame
Panic Disorder Severity Scale
Agoraphobic cognitions
Panic, phobia, generalized anxiety
Trait State Anxiety Inventory (STAI)
Hamilton Anxiety Scale
Pre-test, post-test, 6 months and one year
Beck Depression Inventory
Quality of Life, handicap
Spatial cognition: Rey's Figure and Rod and Frame test
Therapeutic expectations (pre-test)
Therapeutic relationship (post-test)
Dissociative experiences

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026